Systematic and comprehensive investigation of the toxicity of curcuminoid‑essential oil complex: A bioavailable turmeric formulation

Aggarwal,Madan L.; Chacko,Karampendethu M.; Kuruvilla,Binu T.

doi:10.3892/mmr.2015.4579

Systematic and comprehensive investigation of the toxicity of curcuminoid‑essential oil complex: A bioavailable turmeric formulation

Authors:
- Madan L. Aggarwal
- Karampendethu M. Chacko
- Binu T. Kuruvilla
View Affiliations

Affiliations: Shriram Toxicology Centre, Shriram Institute for Industrial Research, Delhi 110007, India, Research and Development Laboratory, Arjuna Natural Extracts Ltd., Keezhmad, Kerala 683112, India
Published online on: November 19, 2015 https://doi.org/10.3892/mmr.2015.4579
Pages: 592-604
Copyright: © Aggarwal et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Curcumin, the active component present in Curcuma longa of the family Zingiberaceae, has a number of pharmacological effects, including potential anti‑inflammatory activity. One of the major limitations of curcumin/turmeric extract is its poor absorption through the gastrointestinal tract. Several approaches have been adopted to increase the bioavailability of curcumin, including loading curcumin into liposomes or nanoparticles, complexation with phospholipids, addition of essential oils and synthesizing structural analogues of curcumin. In the present study, the toxicity and safety of one such bioavailable turmeric formulation, curcuminoid‑essential oil complex (CEC), the toxicity profile of which has not been reported, were examined using in vivo and in vitro models, as per the guidelines of the Organisation for Economic Co-operation and Development. Investigations of acute toxicity study were performed in rats and mice, and the results revealed no signs and symptoms or toxicity or mortality in any of the animals at the maximum recommended dose level of 5,000 mg/kg body weight. The repeated administration of CEC for 90 days in Wistar rats at a dose of 1,000 mg/kg body weight did not induce any observable toxic effects, compared with corresponding control animals. Mutagenicity/genotoxicity investigations were also performed using a bacterial reverse mutation assay (Ames test), a mammalian bone marrow chromosome aberration test and a mammalian erythrocyte micronucleus test in mice. CEC was found to be non‑mutagenic in all three mutagenic investigations. Consequently, the present study indicated that CEC elicited no toxic effects in animals or in vitro. Therefore, following investigations of acute toxicity, repeated dose toxicity and mutagenicity, CEC was deemed a safe, non‑toxic pharmacological formulation.

View Figures

View References

1	Ravindran PN, Nirmal Babu K and Sivaraman K: Turmeric. The golden spice of life. Turmeric The Genus Curcuma Boca Raton, FL, USA: CRC Press; 2007, pp. 1–14
2	Maheshwari RK, Singh AK, Gaddipati J and Srimal RC: Multiple biological effects of curcumin: A short review. Life Sci. 78:2081–2087. 2006. View Article : Google Scholar : PubMed/NCBI
3	Chandra D and Gupta SS: Anti-inflammatory and anti-arthritic activity of volatile oil of Curcuma longa (Haldi). Indian J Med Res. 60:138–142. 1972.PubMed/NCBI
4	Aggarwal BB, Sundaram C, Malani N and Ichikawa H: Curcumin: The Indian solid gold. Adv Exp Med Biol. 595:1–75. 2007. View Article : Google Scholar : PubMed/NCBI
5	Aggarwal BB and Shishodia S: Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 71:1397–1421. 2006. View Article : Google Scholar : PubMed/NCBI
6	Sharma RA, Gescher AJ and Steward WP: Curcumin: The story so far. Eur J Cancer. 41:1955–1968. 2005. View Article : Google Scholar : PubMed/NCBI
7	Duvoix A, Blasius R, Delhalle S, Schnekenburger M, Morceau F, Henry E, Dicato M and Diederich M: Chemopreventive and therapeutic effects of curcumin. Cancer Lett. 223:181–190. 2005. View Article : Google Scholar : PubMed/NCBI
8	Joe B, Vijayakumar M and Lokesh BR: Biological properties of curcumin-cellular and molecular mechanisms of action. Crit Rev Food Sci Nutr. 44:97–111. 2004. View Article : Google Scholar : PubMed/NCBI
9	Menon LG, Kuttan R and Kuttan G: Inhibition of lung metastasis in mice induced by B16F10 melanoma cells by polyphenolic compounds. Cancer Lett. 95:221–225. 1995. View Article : Google Scholar : PubMed/NCBI
10	Menon LG, Kuttan R and Kuttan G: Anti-metastatic activity of curcumin and catechin. Cancer Lett. 141:159–165. 1999. View Article : Google Scholar : PubMed/NCBI
11	Chen HW, Yu SL, Chen JJ, Li HN, Lin YC, Yao PL, Chou HY, Chien CT, Chen WJ, Lee YT and Yang PC: Anti-invasive gene expression profile of curcumin in lung adenocarcinoma based on a high throughput microarray analysis. Mol Pharmacol. 65:99–110. 2004. View Article : Google Scholar : PubMed/NCBI
12	Tønnesen HH, Másson M and Loftsson T: Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: Solubility, chemical and photochemical stability. Int J Pharm. 244:127–135. 2002. View Article : Google Scholar : PubMed/NCBI
13	Pan MH, Huang TM and Lin JK: Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos. 27:486–494. 1999.PubMed/NCBI
14	Johnson JJ and Mukhtar H: Curcumin for chemoprevention of colon cancer. Cancer Lett. 255:170–181. 2007. View Article : Google Scholar : PubMed/NCBI
15	Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, et al: Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin Cancer Res. 10:6847–6854. 2004. View Article : Google Scholar : PubMed/NCBI
16	Anand P, Kunnumakkara AB, Newman RA and Aggarwal BB: Bioavailability of curcumin: Problems and promises. Mol Pharm. 4:807–818. 2007. View Article : Google Scholar : PubMed/NCBI
17	Cui J, Yu B, Zhao Y, Zhu W, Li H, Lou H and Zhai G: Enhancement of oral absorption of curcumin by self-micro-emulsifying drug delivery systems. Int J Pharm. 371:148–155. 2009. View Article : Google Scholar : PubMed/NCBI
18	Marczylo TH, Verschoyle RD, Cooke DN, Morazzoni P, Steward WP and Gescher AJ: Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol. 60:171–177. 2007. View Article : Google Scholar
19	Ganiger S, Malleshappa HN, Krishnappa H, Rajashekhar G, Ramakrishna Rao V and Sullivan F: A two generation reproductive toxicity study with curcumin, turmeric yellow, in Wistar rats. Food Chem Toxicol. 45:64–69. 2007. View Article : Google Scholar
20	Shankar TN, Shantha NV, Ramesh HP, Murthy IA and Murthy VS: Toxicity studies on turmeric (Curcuma longa): Acute toxicity studies in rats, guineapigs and monkeys. Indian J Exp Biol. 18:73–75. 1980.PubMed/NCBI
21	Ravindranath V and Chandrasekhara N: Absorption and tissue distribution of curcumin in rats. Toxicology. 16:259–265. 1980. View Article : Google Scholar : PubMed/NCBI
22	Wahlström B and Blennow G: A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh). 43:86–92. 1978. View Article : Google Scholar
23	Burgos-Morón E, Calderón-Montaño JM, Salvador J, Robles A and López-Lázaro M: The dark side of curcumin. Int J Cancer. 126:1771–1775. 2010.
24	Kizhakkedath R: Clinical evaluation of a formulation containing Curcuma longa and Boswellia serrata extracts in the management of knee osteoarthritis. Mol Med Rep. 8:1542–1548. 2013.PubMed/NCBI
25	EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS): Scientific Opinion on the reevaluation of curcumin (E 100) as a food additive. EFSA Journal. 8:16792010.
26	Joint FAO/WHO Expert Committee on Food Additives (JECFA): Summary and conclusions of the sixty-first meeting. JECF; Rome, Italy: pp. 1–22. 2010
27	Henrotin Y, Priem F and Mobasheri A: Curcumin: a new paradigm and therapeutic opportunity for the treatment of osteoarthritis: curcumin for osteoarthritis management. Springerplus. View Article : Google Scholar
28	Antony B, Merina B, Iyer VS, Judy N, Lennertz K and Joyal S: A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (Biocurcumax), a novel bioenhanced preparation of Curcumin. Indian J Pharm Sci. 70:445–449. 2008. View Article : Google Scholar : PubMed/NCBI
29	OECD Guidelines for Testing of Chemicals. (Acute oral toxicity - fixed dose procedure, test no. 420). Organisation for Economic Co-operation and Development; Paris, France: pp. 1–14. 2002
30	Parasuraman S: Toxicological screening. J Pharmacol Pharmacother. 2:74–79. 2011. View Article : Google Scholar : PubMed/NCBI
31	Maron DM and Ames BN: Revised methods for the Salmonella mutagenicity test. Mutat Res. 113:173–215. 1983. View Article : Google Scholar : PubMed/NCBI
32	Schmid W: The micronucleus test. Mutat Res. 31:9–15. 1975. View Article : Google Scholar : PubMed/NCBI